| Name | Title | Contact Details |
|---|---|---|
JJ Pistoor |
Director of Revenue Operations | Profile |
Allied Healthcare International Inc. is a provider of flexible, or temporary, healthcare staffing to the healthcare industry in the United Kingdom. The Company provides personal or basic care and nursing services in the home, in nursing and care homes
Curve Health is senior care without walls. Founded in April of 2020 on a platform that`s reduced patient transfers from Skilled Nursing Facilities (SNFs) to Emergency Departments by 50%+, Curve advances connected senior care by bridging the silos that hinder healthcare delivery today; enabling physicians to remotely care for patients in SNFs, at home, in ambulances or wherever they may be. Curve combines telemedicine, a health information exchange, predictive analytics and smart billing into a single platform, resulting in higher quality care + significant return on investment, while ensuring the most seamless patient experience.
Choice Connections is a Inver Grove Heights, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
InfraReDx Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Burlington, MA. To find more information about InfraReDx Inc., please visit www.infraredx.com
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.